Literature DB >> 18047933

FOXP3 mRNA expression analysis in the peripheral blood and allograft of heart transplant patients.

I Esmé Dijke1, Kadir Caliskan, Sander S Korevaar, Alex P W M Maat, Pieter E Zondervan, Aggie H M M Balk, Willem Weimar, Carla C Baan.   

Abstract

Previously, we demonstrated in heart transplant patients that FOXP3, a gene required for the development and function of regulatory T cells, was highly expressed in the graft during an acute cellular rejection. In this study, we analyzed whether the FOXP3 gene expression in the peripheral blood also reflects anti-donor immune responses, and therefore may provide clues for non-invasive detection of non-responsiveness or acute rejection. We examined the FOXP3 expression patterns of peripheral blood mononuclear cells (PBMC; n=69) of 19 heart transplant patients during quiescence and rejection in comparison with those of endomyocardial biopsies (EMB; n=75) of 24 heart transplant patients. While the FOXP3 mRNA levels were abundantly expressed in rejecting EMB (ISHLT rejection grade>1R) compared with EMB without histological evidence of myocardial damage (ISHLT rejection grade 0R-1R; p=0.003), no association with rejection or non-responsiveness was found for the FOXP3 mRNA levels in the peripheral blood. Thus, in contrast to intragraft FOXP3 gene expression, the peripheral FOXP3 mRNA levels lack correlation with anti-donor immune responses in the graft, and, consequently, FOXP3 does not appear to be a potential candidate gene for non-invasive diagnosis of non-responsiveness or rejection.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18047933     DOI: 10.1016/j.trim.2007.08.001

Source DB:  PubMed          Journal:  Transpl Immunol        ISSN: 0966-3274            Impact factor:   1.708


  8 in total

1.  Impaired Homocysteine Metabolism Associated with High Plasma Interleukin-17A Levels, a Pro-Atherogenic Marker, in an Endogamous Population of North India.

Authors:  Lovejeet Kaur; Priyanka Rani Garg; Pradeep Kumar Ghosh; Kallur Nava Saraswathy
Journal:  Ethn Dis       Date:  2018-10-18       Impact factor: 1.847

2.  Quantitative in situ analysis of FoxP3+ T regulatory cells on transplant tissue using laser scanning cytometry.

Authors:  Hidenori Takahashi; Phillip Ruiz; Camillo Ricordi; Victor Delacruz; Atsushi Miki; Atsuyoshi Mita; Ryosuke Misawa; Scott Barker; George W Burke; Andreas G Tzakis; Hirohito Ichii
Journal:  Cell Transplant       Date:  2011-09-16       Impact factor: 4.064

3.  The human "Treg MLR": immune monitoring for FOXP3+ T regulatory cell generation.

Authors:  Josh Levitsky; Joshua Miller; Joseph Leventhal; Xuemei Huang; Cathy Flaa; Edward Wang; Anat Tambur; Richard K Burt; Lorenzo Gallon; James M Mathew
Journal:  Transplantation       Date:  2009-12-15       Impact factor: 4.939

Review 4.  T regulatory cells and transplantation tolerance.

Authors:  Vijay S Gorantla; Stefan Schneeberger; Gerald Brandacher; Robert Sucher; Dong Zhang; W P Andrew Lee; Xin Xiao Zheng
Journal:  Transplant Rev (Orlando)       Date:  2010-06-11       Impact factor: 3.943

Review 5.  Mechanism of cellular rejection in transplantation.

Authors:  Elizabeth Ingulli
Journal:  Pediatr Nephrol       Date:  2010-01       Impact factor: 3.714

6.  Levels of Foxp3 in regulatory T cells reflect their functional status in transplantation.

Authors:  Sunil K Chauhan; Daniel R Saban; Hyung K Lee; Reza Dana
Journal:  J Immunol       Date:  2009-01-01       Impact factor: 5.422

7.  Multicenter Analysis of Immune Biomarkers and Heart Transplant Outcomes: Results of the Clinical Trials in Organ Transplantation-05 Study.

Authors:  R C Starling; J Stehlik; D A Baran; B Armstrong; J R Stone; D Ikle; Y Morrison; N D Bridges; P Putheti; T B Strom; M Bhasin; I Guleria; A Chandraker; M Sayegh; K P Daly; D M Briscoe; P S Heeger
Journal:  Am J Transplant       Date:  2015-08-10       Impact factor: 8.086

8.  Biomarkers of transplantation tolerance: more hopeful than helpful?

Authors:  Stephen P Cobbold; Elizabeth Adams; Herman Waldmann
Journal:  Front Immunol       Date:  2011-04-06       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.